Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol for Pain in Pseudoachondroplasia
NCT03866200Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Jun 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of resveratrol in pseudoachondroplasia (PSACH) (2 arms), sponsored by UTHealth Houston. Primary endpoint: Pain as Assessed by Numeric Pain Rating Scale at 90 days. Started Jun 2019; status: terminated.
02
Drugs
resveratrol
03
Conditions
pseudoachondroplasia (PSACH)
Beyond the preview
Go deeper on NCT03866200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866200.